rs869312135
Variant summary
Our verdict is Pathogenic. The variant received 17 ACMG points: 17P and 0B. PM1PM2PM5PP2PP3_ModeratePP5_Very_Strong
The NM_000169.3(GLA):c.62T>C(p.Leu21Pro) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000892 in 112,146 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 1 hemizygotes in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L21F) has been classified as Likely benign.
Frequency
Consequence
NM_000169.3 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 17 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000169.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GLA | NM_000169.3 | MANE Select | c.62T>C | p.Leu21Pro | missense | Exon 1 of 7 | NP_000160.1 | ||
| GLA | NM_001406747.1 | c.62T>C | p.Leu21Pro | missense | Exon 1 of 8 | NP_001393676.1 | |||
| GLA | NM_001406748.1 | c.62T>C | p.Leu21Pro | missense | Exon 1 of 6 | NP_001393677.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| GLA | ENST00000218516.4 | TSL:1 MANE Select | c.62T>C | p.Leu21Pro | missense | Exon 1 of 7 | ENSP00000218516.4 | ||
| RPL36A-HNRNPH2 | ENST00000409170.3 | TSL:4 | c.301-4094A>G | intron | N/A | ENSP00000386655.4 | |||
| GLA | ENST00000649178.1 | c.62T>C | p.Leu21Pro | missense | Exon 1 of 8 | ENSP00000498186.1 |
Frequencies
GnomAD3 genomes AF: 0.00000892 AC: 1AN: 112146Hom.: 0 Cov.: 23 show subpopulations
GnomAD4 exome Cov.: 31
GnomAD4 genome AF: 0.00000892 AC: 1AN: 112146Hom.: 0 Cov.: 23 AF XY: 0.0000291 AC XY: 1AN XY: 34306 show subpopulations
ClinVar
Submissions by phenotype
Fabry disease Pathogenic:3
This variant is not present in population databases (ExAC no frequency). This sequence change replaces leucine with proline at codon 21 of the GLA protein (p.Leu21Pro). The leucine residue is weakly conserved and there is a moderate physicochemical difference between leucine and proline. This variant has been observed in individuals affected with GLA-related conditions (PMID: 26415523, 30038331, Invitae). ClinVar contains an entry for this variant (Variation ID: 217374). This variant has been reported to affect GLA protein function (PMID: 26415523). For these reasons, this allele has been classified as Likely Pathogenic.
GLA c.62T>C is a missense variant that changes the amino acid at residue 21 from Leucine to Proline. This variant has been observed in at least one proband affected with Fabry disease (PMID:26415523;32023956;30038331). At least one functional study has demonstrated a substantial alteration in protein function relative to the wild-type (PMID:32023956;26415523;27657681). It is absent or not present at a significant frequency in gnomAD. In silico models agree that this variant is possibly or probably damaging. In conclusion, we classify GLA p.Leu21Pro (c.62T>C) as a pathogenic variant.
Migalastat response Other:1
Pharmacological Chaperone response: no
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at